11 The toxic effects of desferrioxamine

Bailliere's Clinical Haematology

Volumn 2, Issue 2, 1989, Pages 459-474

  Porter, J B ^a   Huehns, E R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

EYE TOXICITY; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; OTOTOXICITY; REVIEW; YERSINIA ENTEROCOLITICA;

ANIMAL; BLOOD-BRAIN BARRIER; DEFEROXAMINE; DISEASE SUSCEPTIBILITY; EYE DISEASES; GROWTH DISORDERS; HEARING DISORDERS; HUMAN; YERSINIA INFECTIONS;

EID: 0024565607     PISSN: 09503536     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3536(89)80027-7     Document Type: Article

References (104)

1. Successful removal of aluminium from patient with dialysis encephalopathy
2. Desferrioxamine administered intravenously by infusion causes a reduction in the electroretinogram in rabbits anaesthetized with urethane
3. Ocular changes in patients undergoing long-term desferrioxamine treatment
4. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major
5. Acute renal insufficiency occurring during intravenous desferrioxamine therapy
6. Cerebral and ocular toxicity induced by desferrioxamine
7. Lens opacities in thalassemia
8. Mucormycosis infections in dialysis patients
9. Prooxidant action of desferrioxamine: Fenton-like production of hydroxyl radicals by reduced ferrioxamine
10. Visual loss in patient on high-dose subcutaneous desferrioxamine
11. Severe ocular toxicity of desferrioxamine in hemodialyzed patients
12. Rapid desensitisation for desferrioxamine anaphylactoid reaction
13. Life-threatening sepsis complicating heavy metal chelation therapy with desferrioxamine
14. Tier experimentelle pathologische Linsenveranderungen nach langdauernder Verabreichung hoher Dosen von Desferal
15. Enteritis, abscess, and septicemia due to Yersiniaenterocolitica in a child with thalassemia
16. Desferrioxamine B: reversible side effects of high daily doses
17. Desferrioxamine-induced acute neurosensorial deafness
18. Infection with Yersinia enterocolitica in patients with iron overload
19. Ocular effects of systemic siderosis
20. Desferrioxamine in pregnancy
21. Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide
22. Ocular toxicity of high-dose intravenous desferrioxamine
23. Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation
24. Auditory involvement in Thalassaemia Major
25. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia
26. Acute aphasia and loss of vision with desferrioxamine overdose
27. Experimental study of the retinal toxicity of hemoglobinic iron
28. Polyarthritis and Yersinia enterocolitica infection
29. High-dose chelation therapy in thalassaemia
30. Yersiniosis today
31. Cordero: manifestazioni oculari della betathalassemia omozigote
32. Role of iron in microbe-host interactions
33. Complications of deferoxamine therapy
34. Neurotoxicity associated with deferoxamine therapy
35. Yersinia sepsis in patients with iron overload treated with deferoxamine
36. Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major
37. Yersinia pseudotuberculosis septicaemia in thalassaemia major
38. Acute deafness and desferrioxamine
39. The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts
40. Ferrous iron-EDTA-stimulated phospholipid peroxidation
41. ENT complications in thalassaemia major
42. Possible adverse effects of ascorbic acid on cardiac function in patients with myocardial iron overload
43. Mechanisms of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilisation
44. Antibiotics in Yersinia enterocolitica infections
45. The effect of desferrioxamine on fibroblasts and collagen formation in cell cultures
46. Metabolic adaptations of the nephron in renal disease
47. Discussion
48. Discussion
49. Yersinia enterocolitis in iron overload
50. Pneumocysis Carinii. Pneumonia as a complication of desferrioxamine therapy
51. Absence of desferrioxamine teratogenicity in a thalassaemia patient
52. Effects of an iron-chelating agent on pregnant rats. Experimental findings
53. Thalassaemia major. A survey of 138 cases with emphasis on neurologic and muscular aspects
54. A CLINICAL NOTE ON GLAUCOMA
55. Current therapeutic desferrioxamine
56. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
57. Successful pregnancy in β-thalassaemia major
58. Septicaemia due to Yersinia enterocolitica after oral overdoses of iron
59. Rapid desensitisation for desferrioxamine anaphylactic reaction
60. Total management of thalassaemia
61. Advances in the use of iron-chelating agents for the treatment of iron overload
62. Long-term desferrioxamine therapy in thalassaemia
63. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation
64. La funzione uditiva nel morbo di Cooley
65. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions
66. Efficacie comparativa del trattamento con desferriossamina (DFO) in associazione ad emodialisi (HD) e ad emofiltrazione (HF) nei pazienti uremici. Nefrologia, Dialisi, Trapianto
67. Copper chelation and the neuro-ophthalmic toxicity of desferrioxamine
68. Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients
69. Accumulation of iron by Yersiniae
70. Long-term desferrioxamine chelation as a cause of growth failure in thalassaemic patients
71. Hearing loss and desferrioxamine
72. Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA)
73. Treatment of early stages of dialysis encephalopathy by aluminium depletion
74. Zur Frage der Therapie mit aluminumhaltigen Substanzen. Gibt es eine Therapie der Aluminumintoxikation?
75. Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects
76. Comparison of the modes of action of iron chelators using hepatocyte cultures
77. Audiometric abnormalities in thalassaemia; risk factor associated with the use of desferrioxamine
78. Iron mobilisation from hepatocyte monolayer cultures: the importance of membrane permeability and iron binding constant
79. Reassessment of desferrioxamine B in iron overload
80. Continuous subcutaneous administration of desferrioxamine in patients with iron overload
81. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings
82. Yersinia enterocolitica sepsis in splenectomized thalassaemic subjects. Description of 2 cases
83. Iron overdose during pregnancy: successful therapy with deferoxamine
84. DESFERRIOXAMINE AND SYSTEMIC YERSINIOSIS
85. Effects of iron and desferrioxamine on infections with Yersinia enterocolitica
86. Generalised infection with Yersinia enterocolitica and the role of iron
87. Yersiniae and iron. A study in host-parasite relationships
88. Ocular toxicity of desferrioxamine
89. Anaphylactic reactions to desferrioxamine B (DF) in girl with thalassemia and successful rapid desensitization
90. Leukocyte Alkaline Phosphatase (LAP) A Useful Marker of Zinc Status in β-Thalassemic Patients
91. Desferrioxamine, ocular toxicity, and trace metals
92. Successful pregnancy in transfusion-dependent thalassaemia
93. Desensibilizzatione rapida secondo Miller in un bambino con gravi reazioni anafilattiche alla desferrioxamina
94. Thrombocytopenia associated with intravenous desferrioxamine
95. Desferrioxamine in hemodialysis as the cause of Yersinia enterocolitica septicemia
96. Clinical usefulness of iron chelating agents
97. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with G-DTPA